



RELIABLE **TUBERCULOSIS** **BLOOD TESTING.**

For your immunocompromised patients

T-SPOT[®] TB

A MOMENT OF TRUTH

Reliable tuberculosis blood testing for your immunocompromised patients

The T-SPOT®.TB test is a unique, single-visit blood test for tuberculosis (TB) that offers the opportunity to detect latent TB before it becomes active disease. The T-SPOT.TB test is effective with immunocompromised and BCG-vaccinated patient populations and is the only TB blood test without a warning or limitation in its package insert for screening immunocompromised patients.^{1,2}

Immunocompromised patients have an increased risk for TB

Many conditions and treatments can weaken an individual's immune system, making them immunocompromised. Those with compromised immune systems face a higher risk of contracting TB and a higher risk of latent tuberculosis infection (LTBI) becoming active.³

Accurate across patient populations

The T-SPOT.TB test is the only TB test with sensitivity and specificity > 95%¹ — an accuracy that allows clinicians to confidently screen and detect TB infection in challenging patient populations including the immunocompromised. The test uses a proprietary enumeration process that includes washing, counting and standardizing the number of T cells in each specimen, an innovative approach that produces results physicians and patients can trust.

The T-SPOT technology

ISOLATE

Isolate PBMCs

Enriches the desired cell population (T cells) from whole blood

WASH

Wash cells

Enables removal of serum and potentially interfering substances

COUNT

Count cells

Facilitates correction for variations in patient PBMC counts

STANDARDIZE

Standardize cells

Ensures that the required number of cells are used to produce a reportable result

Identifying those at risk

The Centers for Disease Control and Prevention (CDC) has identified the following persons with medical conditions that weaken the immune system and make them at higher risk for developing active TB disease:^{4,5}

- HIV infection (the virus that causes AIDS)
- Substance abuse
- Silicosis
- Diabetes mellitus
- Severe kidney disease
- Low body weight
- Organ transplants
- Head and neck cancer
- Medical treatments such as corticosteroids or organ transplant
- Specialized biologic/biosimilar treatment for rheumatoid arthritis, plaque psoriasis, and inflammatory bowel disease including Crohn's disease and ulcerative colitis among other autoimmune disease

Guidelines for biologic/biosimilar treatment

The American College of Rheumatology (ACR) and American College of Gastroenterology (ACG) recommend screening for hepatitis B (HBV), hepatitis C (HCV) and LTBI in patients starting or currently receiving certain biologic agents.^{6,7,8}

Available through all Quest Diagnostics® Patient Service Centers and numerous regional laboratory partners.

REFERENCES:

1. Oxford Immunotec. T-SPOT.TB Package Insert PI-TB-US-0001 V8. Abingdon, UK. September 2020
2. Qiagen. QuantiFERON-TB Gold Plus (QFT-Plus) ELISA Package Insert. 1095849 Rev. 06. November 2019.
3. Centers for Disease Control and Prevention (CDC). Tuberculosis (TB). Reviewed December 31, 2018. Accessed January 9, 2020. <https://www.cdc.gov/tb/default.htm>
4. Centers for Disease Control and Prevention (CDC). TB risk factors. Reviewed March 18, 2016. Accessed January 8, 2020. <https://www.cdc.gov/tb/topic/basics/risk.htm>
5. Centers for Disease Control and Prevention (CDC). TB 101 for health care workers. Lesson 3: testing for TB infection. Groups at high risk for developing TB disease. Reviewed May 4, 2016.
6. Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. *Arthritis Care Res.* 2012;64(5):625-639. doi:10.1002/acr.21641
7. Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. *Am J Gastroenterol.* 2017;112(2):241-258. doi:10.1038/ajg.2016.537
8. Chebli JMF, Gaburri PD, Chebli LA, et al. A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-α therapy. *Med Sci Monit.* 2014;20:487-498. doi:10.12659/MSM.890331

T-SPOT®.TB

**Oxford
Immunotec**

T-SPOT and the Oxford Immunotec logo are registered trademarks of Oxford Immunotec Ltd.
Quest Diagnostics is a registered trademark of Quest Diagnostics.
© 2021 Oxford Immunotec. All rights reserved.
TB-US-IP-MPN410-0001 V1